恆瑞醫藥(600276.SH):6個產品擬中標第五批全國藥品集採
格隆匯6月23日丨恆瑞醫藥(600276.SH)公佈,根據《中共中央國務院關於深化醫療保障制度改革的意見》和《國務院辦公廳關於推動藥品集中帶量採購工作常態化制度化開展的意見》(國辦發〔2021〕2號)精神,全面實行藥品集中帶量採購,常態化制度化推進藥品集中帶量採購工作,進一步降低羣眾用藥負擔,國家組織開展第五批國家組織藥品集中工作。為積極響應國家號召,2021年6月23日,公司參加了第五批全國藥品集中採購的投標。
根據聯合採購辦公室發佈的全國藥品集中採購擬中選結果公示,公司產品奧沙利鉑注射液、苯磺順阿曲庫銨注射液、度他雄胺軟膠囊、多西他賽注射液、鹽酸羅哌卡因注射液、鹽酸帕洛諾司瓊注射液擬中標本次集中採購。
公司上述擬中標全國藥品第五次集中採購的6個產品,2020年度合計銷售額為255,726萬元,佔公司2020年度營業收入比例為9.22%,2021年第一季度合計銷售額為54,562萬元,佔公司2021年第一季度營業收入比例為7.87%。
本次集中採購是國家組織的第五批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。
本次公司參加投標的碘克沙醇注射液及格隆溴銨注射液未中標,上述2個產品2020年度合計銷售額為187,336萬元,佔公司2020年度營業收入比例為6.75%,2021年第一季度合計銷售額為49,127萬元,佔公司2021年第一季度營業收入比例為7.09%。上述2個產品未中標,會在一定程度上影響產品銷售,但不會對公司生產經營產生重大影響。
今後,公司將積極推進上述產品在其他渠道的銷售推廣,繼續做好同類產品的銷售工作,同時將進一步聚力創新,繼續積極推進創新藥產品在全球市場的上市和銷售,促進公司銷售業績有質量地持續增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.